Hillmen, P., Cairns, D. A., Bloor, A. J. C., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J. G., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Howard, D., Hockaday, A., Jackson, S., …Munir, T. Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA